Blog
RSS FeedPosted by Michael Wonder on 26 Jan 2018
Institute for Clinical and Economic Review releases draft evidence report on emicizumab for haemophilia A
26 January 2018 - Public comment period now open until 23 February 23; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 23 Dec 2017
Institute for Clinical and Economic Review's final report on VMAT2 inhibitors for tardive dyskinesia calls for manufacturer and payer action to lower prices and assure adequate access
22 December 2017 - Evidence suggests drugs offer short-term benefits but are vastly overpriced, leading to “low value” designation and triggering ...
Posted by Michael Wonder on 20 Dec 2017
Institute for Clinical and Economic Review releases draft evidence report on CAR-T therapy for B-cell cancers
19 December 2017 - Public comment period open now until 24 January; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 14 Nov 2017
Institute for Clinical and Economic Review releases draft evidence report on voretigene neparvovec, gene therapy for blindness
14 November 2017 - Public comment period now open until 13 December; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 17 Jul 2017
Institute for Clinical and Economic Review's final evidence report finds prices of anabolic agents for osteoporosis too high, not aligned with potential benefits over other treatments
17 July 2017 - Policy recommendations highlight need for prices to align with clinical benefit, clear guidelines to define highest ...
Posted by Michael Wonder on 13 Jul 2017
ICER releases draft evidence report reviewing olaparib, rucaparib, and niraparib for ovarian cancer
12 July 2017 - Public comment period now open until 9 August; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 28 Jun 2017
ICER evidence report on abuse deterrent opioids finds limited evidence to demonstrate real world impact on opioid abuse
28 June 2017 - With substantially higher costs for abuse-deterrent formulations, and uncertainty regarding their impact on abuse, diversion, and switching ...
Posted by Michael Wonder on 22 Jun 2017
Institute for Clinical and Economic Review releases final value assessment framework for 2017-2019
22 June 2017 - Responds to public comment and sets key parameters for evidence review methods and process for stakeholder engagement. ...
Posted by Michael Wonder on 13 May 2017
Institute for Clinical and Economic Review releases revised evidence report on dupilumab and crisaborole for treatment of atopic dermatitis
12 May 2017 - Limitations noted on the evidence for crisaborole; analyses find stronger evidence for dupilumab and suggest its price ...
Posted by Michael Wonder on 24 Mar 2017
ICER releases draft evidence report on crisaborole and dupilumab for atopic dermatitis
24 March 2017 - Public comment period open until 21 April. ...
Posted by Michael Wonder on 11 Mar 2017
Institute for Clinical and Economic Review releases revised report on targeted immune modulators for treatment of rheumatoid arthritis
10 March 2017 - Analyses of evidence on comparative effectiveness raise questions about current step therapy protocols, while net prices for ...
Posted by Michael Wonder on 07 Mar 2017
Institute for Clinical and Economic Review posts draft scoping document on treatments for ovarian cancer
6 March 2017 - Document will be open to public comment until 27 March 2017. ...
Posted by Michael Wonder on 27 Jan 2017
Institute for Clinical and Economic Review releases evidence report on disease-modifying therapies for multiple sclerosis, including daclizumab and ocrelizumab
26 January 2017 - Report finds alemtuzumab represents best long-term cost-effectiveness; prices for most drugs not well-aligned with added value ...
Posted by Michael Wonder on 22 Jan 2017
ICER releases draft evidence report on treatments for rheumatoid arthritis
20 January 2017 - Public comment period now open - comments accepted until 17 February. ...
Posted by Michael Wonder on 29 Sep 2016
ICER releases draft evidence report on treatments for plaque psoriasis
29 September 2016 - The Institute for Clinical and Economic Review has released a draft evidence report assessing the comparative clinical ...